Cargando…
Simultaneous CXCL12 and ESR1 CpG island hypermethylation correlates with poor prognosis in sporadic breast cancer
BACKGROUND: CXCL12 is a chemokine that is constitutively expressed in many organs and tissues. CXCL12 promoter hypermethylation has been detected in primary breast tumours and contributes to their metastatic potential. It has been shown that the oestrogen receptor α (ESR1) gene can also be silenced...
Autores principales: | Ramos, Edneia AS, Camargo, Anamaria A, Braun, Karin, Slowik, Renata, Cavalli, Iglenir J, Ribeiro, Enilze MSF, Pedrosa, Fábio de O, de Souza, Emanuel M, Costa, Fabrício F, Klassen, Giseli |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834618/ https://www.ncbi.nlm.nih.gov/pubmed/20109227 http://dx.doi.org/10.1186/1471-2407-10-23 |
Ejemplares similares
-
Epigenetic Changes of CXCR4 and Its Ligand CXCL12 as Prognostic Factors for Sporadic Breast Cancer
por: Ramos, Edneia A. S., et al.
Publicado: (2011) -
ADAM33 gene silencing by promoter hypermethylation as a molecular marker in breast invasive lobular carcinoma
por: Seniski, Gerusa G, et al.
Publicado: (2009) -
Fibronectin Affects Transient MMP2 Gene Expression through DNA Demethylation Changes in Non-Invasive Breast Cancer Cell Lines
por: Pereira, Isabela T., et al.
Publicado: (2014) -
CpG island hypermethylation go circular (RNA)
por: Dragomir, Mihnea P., et al.
Publicado: (2018) -
Aberrant CpG Islands Hypermethylation Profiles in Malignant Gliomas
por: Kim, Kwang Ryeol, et al.
Publicado: (2014)